Chemistry Reference
In-Depth Information
21. Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S,
Bonate PL, Ruvuna F, Fram RJ, Jekunen A, et al. Phase I and pharmacokinetic study
of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days
1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res.
2005;11:7825 - 7833.
22. Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A,
Weitman S, Hammond LA. A phase I study of the dolastatin-15 analogue tasidotin
(ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in
patients with advanced solid tumors. Clin. Cancer Res. 2005;11:7807 - 7816.
23. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI.
The isolation and structure of taxol, a novel antileukemic and antitumor agent from
Taxus brevifolia
. J. Am. Chem. Soc. 1971;93:2325 - 2327.
24. Gueritte-Voegelein F, Senilh V, David B, Guenard D, Potier P. Chemical stud-
ies of 10-deacetyl baccatin III. Hemisynthesis of taxol derivatives. Tetrahedron
1986;42:4451 - 4460.
25. Denis J-N, Greene AE, Guenard D, Gueritte-Voegelein F, Mangatal L, Potier P.
A highly efficient, practical approach to natural taxol. J. Am. Chem. Soc. 1988;110:
5917 - 5919.
26. Holton RA, Biediger RJ, Boatman PD. Semisynthesis of taxol and taxotere. In: Taxol:
Science and Applications. Suffness M, ed. 1995. CRC Press, Inc., Boca Raton, FL.
pp. 97 - 121.
27. Suffness M, Wall ME. Discovery and development of taxol. In: Taxol: Science and
Applications. Suffness M, eds. 1995. CRC Press, Inc., Boca Raton, FL. pp. 3 - 25.
28. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly
in vitro
by taxol.
Nature 1979;277:665 - 667.
29. Piccart MJ, Cardoso F. Progress in systemic therapy for breast cancer: an overview
and perspectives. Eur. J. Can. 2003;1 (supp): 56 - 69.
30. Ozols RF. Progress in ovarian cancer: an overview and perspective. Eur. J. Can.
2003;1 (supp): 43 - 55.
31. Davies AM, Lara PN, Mack PC, Gandara DR. Docetaxel in non-small cell lung
cancer: a review. Exp. Opin. Pharmacother. 2003;4:553 - 565.
32. Kamath KR, Barry JJ, Miller KM. The taxus drug-eluting stent: a new paradigm in
controlled drug delivery. Adv. Drug Deliv. Rev. 2006;58:412 - 436.
33. Kingston DGI, Newman DJ. Taxoids: cancer-fighting compounds from nature. Curr.
Opin. Drug Disc. Dev. 2007;10:130 - 144.
34. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Exp. Opin. Phar-
macother. 2006;7:1041 - 1053.
35. Lowe J, Li H, Downing KH, Nogales E. Refined structure of
αβ
-tubulin at 3.5 A
resolution. J. Mol. Biol. 2001;313:1045 - 1057.
36. Paik Y, Yang C, Metaferia B, Tang S, Bane S, Ravindra R, Shanker N, Alcaraz
AA, Johnson SA, Schaefer J, et al. REDOR NMR distance measurements for the
tubulin-bound paclitaxel conformation. J. Am. Chem. Soc. 2007;129:361 - 370.
37. Ganesh T, Guza RC, Bane S, Ravindra R, Shanker N, Lakdawala AS, Snyder JP,
Kingston DGI. The bioactive taxol conformation of
β
-tubulin: Experimental evi-
dence from highly active constrained analogs. Proc. Natl. Acad. Sci. U.S.A. 2004;
101:10006 - 10011.
